natgillin/translations-raw huggingface dataset:
In adults, the most common side effects with PegIntron (seen in more than 1 patient in 10) are viral infection, pharyngitis (sore throat), anaemia (low red blood cell counts), neutropenia (low levels of neutrophils, a type of white blood cell), loss of appetite, depression, anxiety, emotional lability (mood swings), impaired concentration, insomnia (difficulty sleeping), headache, dizziness, dyspnoea (difficulty breathing), cough, vomiting, nausea (feeling sick), abdominal pain (stomach ache), diarrhoea, dry mouth, alopecia (hair loss), pruritus (itching), dry skin, rash, myalgia (muscle pain), arthralgia (joint pain), musculoskeletal pain (pain in the muscles and bones), reactions at the site of the injection, inflammation at the site of the injection, fatigue (tiredness), asthenia (weakness), irritability, chills, pyrexia (fever), influenza (flu)-like illness and weight loss.
Pri odraslih bolnikih so bili najpogostejši neželeni učinki zdravila PegIntron (opaženi pri več kot 1 bolniku od 10) virusne okužbe, faringitis (vneto žrelo), anemija (nizke ravni rdečih krvnih celic), nevtropenija (nizke ravni nevtrofilcev, vrste belih krvnih celic), izguba teka, depresija, anksioznost, čustvena labilnost (nihanje razpoloženja), motnje koncentracije, nespečnost (težave s spanjem), glavobol, omotica, dispneja (oteženo dihanje), kašelj, bruhanje, navzeja (občutek slabosti), bolečine v trebuhu, driska, suha usta, alopecija (izpadanje las), pruritus (srbenje), suha koža, izpuščaji, mialgija (bolečine v mišicah), artralgija (bolečine v sklepih), mišično-skeletne bolečine (bolečine v mišicah in kosteh), reakcije na mestu injiciranja, vnetje na mestu injiciranja, utrujenost, astenija (šibkost), razdražljivost, mrzlica, pireksija (povišana telesna temperatura), gripi podobna bolezen in izguba telesne mase.
Other information about PegIntron:
Druge informacije o zdravilu PegIntron:
The full EPAR for PegIntron can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo PegIntron je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This document is a summary of the European Public Assessment Report (EPAR) for PegIntron.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo PegIntron.
For more information about treatment with PegIntron, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom PegIntron preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
The CHMP decided that PegIntron's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila PegIntron večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Because PegIntron is linked to side effects such as depression, patients must be closely monitored during treatment.
Ker je zdravilo PegIntron povezano z neželenimi učinki, kot je depresija, je treba bolnike med zdravljenjem pozorno spremljati.
What benefit has PegIntron shown during the studies?
Kakšne koristi je zdravilo PegIntron izkazalo med študijami?
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for PegIntron.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo PegIntron, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
PegIntron is also linked to weight loss and reduced growth in children and adolescents.
Zdravilo PegIntron je povezano z izgubljanjem telesne mase in zmanjšano telesno rastjo pri otrocih in mladostnikih.
Treatment with PegIntron should be started and supervised by a doctor who has experience in the management of patients with hepatitis C. PegIntron is given once a week as an injection under the skin.
Zdravljenje z zdravilom PegIntron mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem bolnikov s hepatitisom C. Zdravilo PegIntron se daje enkrat tedensko z injekcijo v podkožje.
What is the risk associated with PegIntron?
Kakšna tveganja so povezana z zdravilom PegIntron?
PegIntron must not be used in patients with a severe medical condition, severe liver problems, thyroid disease that is not controlled, epilepsy or other central nervous system problems.
Zdravilo PegIntron se ne sme uporabljati pri bolnikih z resnim obolenjem, s hudimi težavami z jetri, z nenadzorovanim obolenjem ščitnice, epilepsijo ali drugimi motnjami delovanja osrednjega živčnega sistema.
The combination of PegIntron with ribavirin was effective in patients with cirrhosis and in patients infected with HIV.
Kombinacija zdravila PegIntron in ribavirina je bila učinkovita pri bolnikih s cirozo in bolnikih, okuženih z virusom HIV.
PegIntron must not be used in people who are hypersensitive (allergic) to any interferon or any of the other ingredients.
Zdravila PegIntron ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) katero koli vrsto interferona ali katero drugo sestavino zdravila.
In other adults with hepatitis C virus in their blood, including patients also infected with human immunodeficiency virus (HIV), PegIntron is given either with ribavirin (dual therapy) or on its own if they cannot take ribavirin.
Ostalim odraslim z virusom hepatitisa C v krvi, vključno z bolniki, ki so okuženi tudi z virusom humane imunske pomanjkljivosti (HIV), se PegIntron daje bodisi z ribavirinom (dvotirno zdravljenje) bodisi kot samostojno zdravilo, če bolniki ne morejo jemati ribavirina.
The combination of PegIntron and ribavirin has also been studied in one study involving 1,354 adults whose previous treatment had failed and in one study involving 107 children and adolescents aged between three and 17 years who had not been treated before.
Kombinacijo zdravila PegIntron in ribavirina so proučevali tudi v študiji s 1 354 odraslimi bolniki, pri katerih predhodno zdravljenje ni bilo uspešno, in študiji s 107 otroki in mladostniki, starimi od 3 do 17 let, ki pred tem še niso bili zdravljeni.
PegIntron can be given in a triple therapy combination with ribavirin and boceprevir to adults with type 1 hepatitis C whose liver is damaged but still able to work normally (compensated liver disease).
Zdravilo PegIntron se lahko daje v okviru trotirnega zdravljenja v kombinaciji z ribavirinom in boceprevirjem odraslim bolnikom s hepatitisom C tipa 1, katerih jetra so poškodovana, vendar še vedno normalno delujejo (kompenzirana bolezen jeter).
For the full list of all side effects reported with PegIntron, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila PegIntron, glejte navodilo za uporabo.
PegIntron, with or without ribavirin, has been compared with interferon alfa-2b in five main studies involving a total of over 6,000 adults with hepatitis C who had not been treated before, including 328 patients with cirrhosis and 507 patients also infected with HIV.
Zdravilo PegIntron, uporabljeno sočasno z ribavirinom ali brez njega, so primerjali z interferonom alfa-2b v petih glavnih študijah s skupno več kot 6 000 odraslih bolnikov s hepatitisom C, ki predhodno še niso bili zdravljeni, vključno s 328 bolniki s cirozo in 507 bolniki, ki so bili okuženi tudi z virusom HIV.
In children and adolescents receiving PegIntron in combination with ribavirin, side effects were similar to adults, although reduced growth was also seen in more than 1 patient in 10.
Pri otrocih in mladostnikih, ki so prejemali kombinacijo zdravila PegIntron in ribavirina, so bili neželeni učinki podobni kot pri odraslih, čeprav je bila pri več kot 1 bolniku od 10 opažena tudi manjša telesna rast.
The interferon alfa-2b in PegIntron is produced by a method known as ‘recombinant DNA technology': it is made by a bacterium that has received a gene (DNA), which makes it able to produce interferon alfa-2b.
Interferon alfa-2b, ki ga vsebuje zdravilo PegIntron, se proizvaja po metodi, imenovani „tehnologija rekombinantne DNK“, pri kateri bakterija prejme gen (DNK), s katerim lahko tvori interferon alfa-2b.
Why has PegIntron been approved?
Zakaj je bilo zdravilo PegIntron odobreno?
PegIntron is a medicine that contains the active substance peginterferon alfa-2b.
PegIntron je zdravilo, ki vsebuje zdravilno učinkovino peginterferon alfa-2b.
In adults (aged 18 years and older), PegIntron can be used in patients who have not been treated before or whose previous treatment failed.
Zdravilo PegIntron se lahko uporablja pri odraslih bolnikih (starih vsaj 18 let), ki še niso bili zdravljeni oziroma pri katerih predhodno zdravljenje ni bilo uspešno.
Two main studies involving 1,503 adult patients with type 1 hepatitis C and compensated liver disease investigated the effect of PegIntron in a triple therapy combination with ribavirin and boceprevir compared with PegIntron and ribavirin alone.
V dveh glavnih študijah, v katerih so sodelovali 1 503 odrasli bolniki s hepatitisom C tipa 1 in kompenzirano boleznijo jeter, so preučevali učinek zdravila PegIntron v trotirnem zdravljenju z ribavirinom in boceprevirjem v primerjavi z njegovim učinkom v kombinaciji zgolj z ribavirinom.
PegIntron is used to treat long-term hepatitis C (a disease of the liver due to infection with the hepatitis C virus) in patients aged three years and older.
Zdravilo PegIntron se uporablja za zdravljenje bolnikov, starejših od treh let, z dolgotrajnim hepatitisom C (boleznijo jeter, ki je posledica okužbe z virusom hepatitisa C).
In adults, PegIntron was more effective than interferon alfa-2b in patients who had not been treated before, with around a quarter of the patients responding to PegIntron alone and around a half responding to the combination of PegIntron and ribavirin.
Pri odraslih bolnikih, ki predhodno še niso bili zdravljeni, je bilo zdravilo PegIntron učinkovitejše od interferona alfa-2b, pri čemer se jih je približno četrtina odzvala na zdravilo, vzeto samostojno, približno polovica pa na kombinacijo zdravila PegIntron in ribavirina.
In the studies on triple therapy in patients with type 1 hepatitis C and compensated liver disease, PegIntron in combination with ribavirin and boceprevir was shown to be more effective than the dual combination of PegIntron with ribavirin alone.
V študijah trotirnega zdravljenja bolnikov s hepatitisom C tipa 1 in kompenzirano boleznijo jeter se je zdravljenje z zdravilom PegIntron v kombinaciji z ribavirinom in boceprevirjem izkazalo za učinkovitejše od dvotirnega zdravljenja z zdravilom PegIntron in ribavirinom.
Triple therapy led to an increase of about 30% in the number of previously untreated early responders who were cured.
Pri trotirnem zdravljenju se je število predhodno nezdravljenih bolnikov, ki so se zgodaj odzvali na zdravljenje in so bili ozdravljeni, povečalo za približno 30 %.
There is also a marked increase in cure rates in patients with long-term type 1 hepatitis C when given the triple therapy of PegIntron in combination with ribavirin and boceprevir.
Opaziti je tudi znatno povečanje deleža ozdravljenih bolnikov z dolgotrajno okužbo s hepatitisom C tipa 1 pri trotirnem zdravljenju z zdravilom PegIntron v kombinaciji z ribavirinom in boceprevirjem.
Depending on the severity of the side effects treatment may have to be stopped altogether (including boceprevir).Patients can inject themselves once they have been trained appropriately.
Glede na resnost neželenih učinkov bo morda treba z zdravljenjem (tudi z boceprevirjem) popolnoma prenehati.
In PegIntron, the interferon alfa-2b has been ‘pegylated' (attached to a chemical called polyethylene glycol).
V zdravilu PegIntron je interferon alfa-2b „pegiliran“ (vezan na kemično snov, imenovano polietilenglikol).
What is PegIntron used for?
Za kaj se zdravilo PegIntron uporablja?
The active substance in PegIntron, peginterferon alfa-2b, belongs to the group ‘interferons'.
Zdravilna učinkovina zdravila PegIntron, peginterferon alfa-2b, spada v skupino interferonov.
How does PegIntron work?
Kako zdravilo PegIntron deluje?
What is PegIntron?
Kaj je zdravilo PegIntron?
How has PegIntron been studied?
Kako je bilo zdravilo PegIntron raziskano?
How is PegIntron used?
Kako se zdravilo PegIntron uporablja?
Around a quarter of the adults whose previous treatment had failed and around two-thirds of the children and adolescents responded to treatment with PegIntron and ribavirin.
Na zdravljenje s kombinacijo zdravila PegIntron in ribavirina se je odzvala približno četrtina odraslih bolnikov, pri katerih predhodno zdravljenje ni bilo uspešno, in okoli dve tretjini otrok in mladostnikov.
The doses of ribavirin and PegIntron may need to be adjusted for patients who experience side effects.
Pri bolnikih, pri katerih se pojavijo neželeni učinki, bo odmerek ribavirina in zdravila PegIntron morda treba prilagoditi.
The Member States shall ensure that the MAH provides all physicians who are expected to prescribe or use Tamiflu a Direct Healthcare Professional Communication (DHPC) letter, the text of which is appended to the CHMP assessment report.
Države članice morajo zagotoviti, da bo imetnik dovoljenja za promet vsem zdravnikom, za katere se pričakuje, da bodo predpisovali zdravilo Tamiflu, razposlal pomembno obvestilo zdravstvenim delavcem (Direct Healthcare Professional Communication letter - DHPC) z vsebino, ki je priložena poročilu CHMP.
The Member States shall agree with the MAH the communication plan for the DHPC letter.
Države članice se morajo z imetnikom dovoljenja za promet dogovoriti glede komunikacijskega načrta v zvezi z DHPC obvestilom.
The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented.
Države članice morajo zagotoviti, da so vsi pogoji in omejitve v zvezi z varno in učinkovito uporabo zdravila opisani spodaj implementirani.
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
POGOJI IN OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH MORA IMPLEMENTIRATI DRŽAVA ČLANICA
ANNEX CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
PRILOGA POGOJI IN OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH MORA IMPLEMENTIRATI DRŽAVA ČLANICA
Overall, the safety profile was considered acceptable.
Na splošno je bil varnostni profil zdravila ocenjen kot sprejemljiv.
Further information on the orphan designation can be found here: ema.europa.eu/medicines/human/orphan-designations/eu3151551
Nadaljnje informacije glede določitve zdravila sirote lahko najdete tukaj: ema.europa.eu/medicines/human/orphan-designations/eu3151551
The doctor may decide that patients or their caregivers can inject the medicine themselves after they have been properly trained.
Zdravnik bo morda odobril, da lahko bolnik ali njegov negovalec sama injicirata zdravilo, potem sta bila ustrezno usposobljena.
The recommended starting dose of Takhzyro is 300 mg every 2 weeks.
Priporočeni začetni odmerek zdravila Takhzyro je 300 mg vsaka dva tedna.
The European Medicines Agency therefore decided that Takhzyro's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Takhzyro večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Further information on Takhzyro can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Takhzyro.
Nadaljnje informacije o zdravilu Takhzyro so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/Takhzyro.
What measures are being taken to ensure the safe and effective use of Takhzyro?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Takhzyro?
Patients experienced on average 0.3 attacks per month when given Takhzyro injections every 2 weeks and 0.5 attacks when given injections every 4 weeks.
Bolniki so v povprečju doživeli 0,3 napada na mesec, kadar so prejemali injekcije zdravila Takhzyro vsaka dva tedna, in 0,5 napada, kadar so injekcije prejemali vsake štiri tedne.
As for all medicines, data on the use of Takhzyro are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Takhzyro stalno spremljajo.
Side effects reported with Takhzyro are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Takhzyro, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Takhzyro have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Takhzyro upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Other information about Takhzyro
Druge informacije o zdravilu Takhzyro
Hereditary angioedema is rare, and Takhzyro was designated an ‘orphan medicine' (a medicine used in rare diseases) on 9 October 2015.
Hereditarni angioedem je redka bolezen, zato je bilo zdravilo Takhzyro 9. oktobra 2015 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
Attacks of hereditary angioedema can be life threatening when the swelling around the throat presses against the airway.
Napadi hereditarnega angioedema so lahko življenjsko nevarni, kadar oteklina okrog grla pritiska na dihalne poti.
Why is Takhzyro authorised in the EU?
Zakaj je zdravilo Takhzyro odobreno v EU?
For more information about using Takhzyro, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Takhzyro glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
The most common side effects with Takhzyro (which may affect more than 1 patient in 10) are reactions at the site of injection including erythema (redness), bruising and pain.
Najpogostejši neželeni učinki zdravila Takhzyro (ki se lahko pojavijo pri največ 1 bolniku od 10) so reakcije na mestu injiciranja, vključno z eritemom (rdečina), podplutbo in bolečino.
If the patient remains free of attacks with the two-weekly dose, the doctor can reduce the frequency to once every 4 weeks.
Če bolnik med dvotedenskim odmerkom ni imel napada, lahko zdravnik spremeni pogostost jemanja na vsake štiri tedne.
Patients with angioedema have rapid swelling under the skin in areas such as the face, throat, arms and legs.
Pri bolnikih z angioedemom pride do hitrega otekanja pod kožo na različnih delih telesa, na primer na obrazu, grlu, rokah in nogah.
An overview of Takhzyro and why it is authorised in the EU
Pregled zdravila Takhzyro in zakaj je odobreno v EU
What benefits of Takhzyro have been shown in studies?
Kakšne koristi je zdravilo Takhzyro izkazalo v študijah?
What are the risks associated with Takhzyro?
Kakšna tveganja so povezana z zdravilom Takhzyro?
What is Takhzyro and what is it used for?
Kaj je zdravilo Takhzyro in za kaj se uporablja?
Patients with hereditary angioedema have high levels of a substance called ‘bradykinin', which causes blood vessels to widen and leak fluid into the surrounding tissue leading to the swelling attacks seen in angioedema.
Pri bolnikih s hereditarnim angioedemom nastajajo v krvnem obtoku visoke ravni snovi, imenovane „bradikinin“, ki povzročijo, da se krvne žile razširijo in prepuščajo tekočino v okoliško tkivo, kar povzroči napade otekanja, kot jih je mogoče opaziti pri angioedemu.
By blocking the actions of kallikrein, lanadelumab helps to prevent the swelling and related symptoms of angioedema.
Lanadelumab z zaviranjem delovanja kalikreina pomaga pri preprečevanju otekanja in drugih simptomov angioedema.
Takhzyro can only be obtained with a prescription and should be started under supervision of a doctor experienced in managing hereditary angioedema.
Predpisovanje in izdaja zdravila Takhzyro je le na recept, zdravljenje z njim pa se sme uvesti samo pod nadzorom zdravnika z izkušnjami z zdravljenjem hereditarnega angioedema.
For the full list of side effects and restrictions with Takhzyro, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Takhzyro glejte navodilo za uporabo.
The active substance in Takhzyro, lanadelumab, works by attaching to and blocking an enzyme in the blood called 'kallikrein', which has several functions, including increasing levels of bradykinin.
Učinkovina v zdravilu Takhzyro, lanadelumab, deluje tako, da se veže na encim v krvi, imenovan „kalikrein“, in ga zavira, kar med drugim povzroči nastajanje visokih ravni bradikinina.
Takhzyro is given as an injection under the skin, preferably in the abdomen (belly), thighs or upper arms.
Zdravilo Takhzyro se daje z injiciranjem pod kožo, po možnosti v abdomen (trebuh), stegno ali nadlaket.
Takhzyro is a medicine used to prevent attacks of hereditary angioedema in patients aged 12 years and over.
Takhzyro je zdravilo, ki se uporablja pri bolnikih, starih 12 let in več, za preprečevanje napadov hereditarnega angioedema (HAE).
Takhzyro is effective in preventing angioedema attacks and the fact that it only needs to be given every 2 or 4 weeks was considered an advantage over existing treatments.
Dejstvo, da ga je treba injicirati vsaka dva tedna ali vsake štiri tedne, naj bi imelo prednosti pred obstoječimi zdravljenji.
How does Takhzyro work?
Kako zdravilo Takhzyro deluje?
How is Takhzyro used?
Kako se zdravilo Takhzyro uporablja?
Takhzyro was found to be effective in reducing the number of angioedema attacks in a main study in 126 adults and children above 12 years of age with hereditary angioedema.
V glavni študiji, v katero je bilo vključenih 126 odraslih in otrok, starejših od 12 let, s heriditarnim angioedemom, je bilo ugotovljeno, da je zdravilo Takhzyro učinkovito pri zniževanju števila napadov angioedema.
This compared with 2 attacks per month for patients on placebo (a dummy treatment).
Bolniki, ki so jemali placebo (zdravilo brez učinkovine), so za primerjavo doživeli dva napada na mesec.
• if you think you may need any vaccinations in the near future, including vaccinations for travel to other countries.
• če menite, da boste v kratkem potrebovali katero koli cepljenje, vključno s cepljenji za potovanje v druge države.
Key results from all four studies are summarised in table 4.
Ključni rezultati vseh štirih preskušanj so povzeti v preglednici 4.
Your doctor will decide if you should receive other treatment at the same time.
Zdravnik se bo odločil, ali boste sočasno prejeli tudi druge oblike zdravljenja.
Do not have Rituzena if you have an active infection or a serious problem with your
Zdravila Rituzena ne smete prejeti, če imate aktivno okužbo ali resno težavo s svojim
p-value (Wald test, not
p-vrednost (test Wald, ni prilagojen)
Rituzena may also cause changes in laboratory tests carried out by your doctor.
Zdravilo Rituzena lahko vpliva tudi na spremembe laboratorijskih preiskav, ki jih naroči vaš zdravnik.
Patients should also be advised to inform their partner or caregivers about their treatment, since they may notice symptoms that the patient is not aware of.
Bolnikom je treba naročiti, naj o svojem zdravljenju obvestijo partnerja ali skrbnike, ker bodo morda ti opazili simptome, ki se jih bolniki ne
The spread of these abnormal B-lymphocytes is the cause of symptoms you may have.
Nastajanje teh nenormalnih limfocitov B je vzrok simptomom, ki jih morda imate.
Read this leaflet carefully before you start taking this medicine because it contains important
Pred začetkom jemanja zdravila natančno preberite navodilo, ker vsebuje za vas pomembne